Mucosolvan 15 mg - mucolytic 20 gummy tablets

Product Description

Gummies

Active ingredients

One gummy lozenge contains: ambroxol hydrochloride 15 mg.

Excipients

Acacia, sorbitol, karion 83 (mixture of sorbitol, mannitol, hydrogenated oligosaccharides), peppermint oil, eucalyptus oil, sodium saccharin, liquid paraffin, purified water.

Therapeutic indications

Treatment of secretion disorders in acute and chronic bronchopulmonary diseases.

Contraindications

Hypersensitivity to the active ingredient or to any of the excipients. Severe liver and kidney disorders. The drug is contraindicated in case of rare hereditary diseases that may be incompatible with one of the excipients.

Dosage

The following dosages are recommended unless otherwise prescribed by your doctor: Adults and children over 12 years: 2 gummy lozenges 3 times a day. Children between 6 and 12 years: 1 gummy lozenge 2–3 times a day. Caution: Do not exceed the indicated dose without medical advice. Dissolve the gummy lozenge slowly in your mouth. Use only for short periods of treatment (no more than two weeks). Can be administered to patients with diabetes. Mucosolvan can be taken without regard to meals. In acute respiratory conditions, consult your doctor if symptoms do not improve or worsen during treatment with Mucosolvan.

Warnings and precautions

Ambroxol hydrochloride should be administered with caution to patients with peptic ulcers. In very few cases, serious skin lesions such as Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN) have been observed in conjunction with the administration of expectorants such as ambroxol. Most of these could be explained by the severity of underlying diseases or other concomitant medications. Furthermore, in the initial phase of Stevens-Johnson syndrome or toxic epidermal necrolysis (TEN), patients may initially experience nonspecific flu-like symptoms, such as fever, chills, rhinitis, cough, and sore throat. Due to these misleading symptoms, symptomatic treatment with cough and cold therapy may be initiated. If new skin or mucous membrane lesions occur, consult your doctor immediately and discontinue treatment with ambroxol hydrochloride as a precaution. In case of impaired renal function, Mucosolvan can be used only after consulting your doctor. Important information about some of the excipients: The lozenges contain sorbitol (1 lozenge contains 366 mg of sorbitol corresponding to 2.2 g of sorbitol per maximum recommended daily dose (90 mg); the caloric value of sorbitol is 2.6 kcal/g): patients with rare hereditary problems of fructose intolerance should not take this medicine.

Interactions

Following the administration of ambroxol, the concentrations of antibiotics (amoxicillin, cefuroxime, erythromycin) in bronchopulmonary secretions and saliva are increased. No interactions with other medicinal products have been reported.